JP2014501740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501740A5 JP2014501740A5 JP2013544980A JP2013544980A JP2014501740A5 JP 2014501740 A5 JP2014501740 A5 JP 2014501740A5 JP 2013544980 A JP2013544980 A JP 2013544980A JP 2013544980 A JP2013544980 A JP 2013544980A JP 2014501740 A5 JP2014501740 A5 JP 2014501740A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- effective amount
- medicament
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 70
- 150000003839 salts Chemical class 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 29
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 206010033799 Paralysis Diseases 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 description 21
- 125000003342 alkenyl group Chemical group 0.000 description 16
- 125000003545 alkoxy group Chemical group 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 16
- 125000000304 alkynyl group Chemical group 0.000 description 16
- 125000001153 fluoro group Chemical group F* 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 125000002252 acyl group Chemical group 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 6
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 description 5
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 3
- 208000024571 Pick disease Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 208000034799 Tauopathies Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000006308 propyl amino group Chemical group 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- JOKKFZJLPKIPOS-FMDGEEDCSA-N (3ar,5r,6r,7r,7ar)-2-(dimethylamino)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(N(C)C)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2F JOKKFZJLPKIPOS-FMDGEEDCSA-N 0.000 description 1
- ICJGJSLPQBWFGV-FMDGEEDCSA-N (3ar,5r,6r,7r,7ar)-2-(ethylamino)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2F ICJGJSLPQBWFGV-FMDGEEDCSA-N 0.000 description 1
- KFTTUHTWIAVGRH-NYMZXIIRSA-N (3ar,5r,6r,7r,7ar)-7-fluoro-5-(hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(NC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2F KFTTUHTWIAVGRH-NYMZXIIRSA-N 0.000 description 1
- VKALMUKKLOGDPG-JGKVKWKGSA-N (3ar,5r,6r,7r,7ar)-7-fluoro-5-(hydroxymethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(NCCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2F VKALMUKKLOGDPG-JGKVKWKGSA-N 0.000 description 1
- JOKKFZJLPKIPOS-OZRXBMAMSA-N (3ar,5r,6r,7s,7ar)-2-(dimethylamino)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(N(C)C)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]2F JOKKFZJLPKIPOS-OZRXBMAMSA-N 0.000 description 1
- ICJGJSLPQBWFGV-OZRXBMAMSA-N (3ar,5r,6r,7s,7ar)-2-(ethylamino)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]2F ICJGJSLPQBWFGV-OZRXBMAMSA-N 0.000 description 1
- KFTTUHTWIAVGRH-IECVIRLLSA-N (3ar,5r,6r,7s,7ar)-7-fluoro-5-(hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(NC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]2F KFTTUHTWIAVGRH-IECVIRLLSA-N 0.000 description 1
- VKALMUKKLOGDPG-ANZWQOBJSA-N (3ar,5r,6r,7s,7ar)-7-fluoro-5-(hydroxymethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(NCCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]2F VKALMUKKLOGDPG-ANZWQOBJSA-N 0.000 description 1
- AMTGNXFFSFQYJA-ULAWRXDQSA-N (3ar,5r,6s,7ar)-2-(dimethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound C1[C@H](O)[C@@H](CO)O[C@@H]2SC(N(C)C)=N[C@@H]21 AMTGNXFFSFQYJA-ULAWRXDQSA-N 0.000 description 1
- WYAROEYZBMXNIZ-ULAWRXDQSA-N (3ar,5r,6s,7ar)-2-(ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound C1[C@H](O)[C@@H](CO)O[C@@H]2SC(NCC)=N[C@@H]21 WYAROEYZBMXNIZ-ULAWRXDQSA-N 0.000 description 1
- VYBSQCAXXNKUFN-JGWLITMVSA-N (3ar,5r,6s,7ar)-2-amino-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound C1[C@H](O)[C@@H](CO)O[C@@H]2SC(N)=N[C@@H]21 VYBSQCAXXNKUFN-JGWLITMVSA-N 0.000 description 1
- UMXYJFMLLLIFPW-XZBKPIIZSA-N (3ar,5r,6s,7ar)-5-(hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound C1[C@H](O)[C@@H](CO)O[C@@H]2SC(NC)=N[C@@H]21 UMXYJFMLLLIFPW-XZBKPIIZSA-N 0.000 description 1
- CMTNETCUCXXJBO-BZNPZCIMSA-N (3ar,5r,6s,7ar)-5-(hydroxymethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound C1[C@H](O)[C@@H](CO)O[C@@H]2SC(NCCC)=N[C@@H]21 CMTNETCUCXXJBO-BZNPZCIMSA-N 0.000 description 1
- NVPHCPSHUAUQSI-FMDGEEDCSA-N (3ar,5r,6s,7r,7ar)-2-(ethylamino)-5-methyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C)[C@@H](O)[C@@H]2O NVPHCPSHUAUQSI-FMDGEEDCSA-N 0.000 description 1
- KFTTUHTWIAVGRH-BNWJMWRWSA-N (3ar,5r,6s,7r,7ar)-7-fluoro-5-(hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(NC)=N[C@H]2[C@@H]1O[C@H](CO)[C@H](O)[C@@H]2F KFTTUHTWIAVGRH-BNWJMWRWSA-N 0.000 description 1
- ZMLWGEHWECDGGA-RLZVPWTLSA-N (3ar,5s,6r,7r,7ar)-5-(difluoromethyl)-7-fluoro-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(NC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2F ZMLWGEHWECDGGA-RLZVPWTLSA-N 0.000 description 1
- XFEVUYIVNQYKSO-NYMZXIIRSA-N (3ar,5s,6r,7r,7ar)-7-fluoro-5-(fluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(NC)=N[C@H]2[C@@H]1O[C@H](CF)[C@@H](O)[C@@H]2F XFEVUYIVNQYKSO-NYMZXIIRSA-N 0.000 description 1
- ZMLWGEHWECDGGA-SDDMPLOYSA-N (3ar,5s,6r,7s,7ar)-5-(difluoromethyl)-7-fluoro-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S1C(NC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@H]2F ZMLWGEHWECDGGA-SDDMPLOYSA-N 0.000 description 1
- PGGPTJXWYICMCH-FZGKIIIMSA-N (3ar,5s,6s,7ar)-5-(difluoromethyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound C1[C@H](O)[C@@H](C(F)F)O[C@@H]2SC(N(C)C)=N[C@@H]21 PGGPTJXWYICMCH-FZGKIIIMSA-N 0.000 description 1
- INFUQWHUNQRCMN-UELCQGJWSA-N (3ar,5s,6s,7ar)-5-(difluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-6-ol Chemical compound C1[C@H](O)[C@@H](C(F)F)O[C@@H]2SC(NC)=N[C@@H]21 INFUQWHUNQRCMN-UELCQGJWSA-N 0.000 description 1
- QGBWBARJAAJENQ-CRYJZLASSA-N (3ar,5s,6s,7r,7ar)-2-(azetidin-1-yl)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound N([C@@H]1[C@H]([C@@H]([C@@H](C(F)F)O[C@@H]1S1)O)O)=C1N1CCC1 QGBWBARJAAJENQ-CRYJZLASSA-N 0.000 description 1
- SDGWDCUMNQRMGT-JGKVKWKGSA-N (3ar,5s,6s,7r,7ar)-2-(azetidin-1-yl)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound N([C@@H]1[C@H]([C@@H]([C@@H](CF)O[C@@H]1S1)O)O)=C1N1CCC1 SDGWDCUMNQRMGT-JGKVKWKGSA-N 0.000 description 1
- NSRPCECGVYAJLW-LVBGKUAWSA-N (3ar,5s,6s,7r,7ar)-2-amino-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(N)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O NSRPCECGVYAJLW-LVBGKUAWSA-N 0.000 description 1
- UKHGAZWRCYQCML-QZABAPFNSA-N (3ar,5s,6s,7r,7ar)-2-amino-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(N)=N[C@H]2[C@@H]1O[C@H](CF)[C@@H](O)[C@@H]2O UKHGAZWRCYQCML-QZABAPFNSA-N 0.000 description 1
- SXPPQYRVMAWUCR-CRYJZLASSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(prop-2-ynylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound O1[C@H](C(F)F)[C@@H](O)[C@H](O)[C@H]2N=C(NCC#C)S[C@H]21 SXPPQYRVMAWUCR-CRYJZLASSA-N 0.000 description 1
- 208000023697 ABri amyloidosis Diseases 0.000 description 1
- 208000017227 ADan amyloidosis Diseases 0.000 description 1
- 206010058285 Allergy to arthropod bite Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019315 Heart transplant rejection Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 description 1
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010023439 Kidney transplant rejection Diseases 0.000 description 1
- 206010024715 Liver transplant rejection Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010051604 Lung transplant rejection Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010049169 Pancreas transplant rejection Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000009564 autosomal recessive limb-girdle muscular dystrophy type 2A Diseases 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000035802 chromosome 17 disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 208000017004 dementia pugilistica Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- -1 salt compound Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426773P | 2010-12-23 | 2010-12-23 | |
| US61/426,773 | 2010-12-23 | ||
| CNPCT/CN2011/074569 | 2011-05-24 | ||
| PCT/CN2011/074569 WO2012159262A1 (en) | 2011-05-24 | 2011-05-24 | Selective glycosidase inhibitors and uses thereof |
| US201161507684P | 2011-07-14 | 2011-07-14 | |
| US61/507,684 | 2011-07-14 | ||
| PCT/CA2011/001397 WO2012083435A1 (en) | 2010-12-23 | 2011-12-21 | Selective glycosidase inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015230912A Division JP6322177B2 (ja) | 2010-12-23 | 2015-11-26 | 選択的グルコシダーゼインヒビターおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014501740A JP2014501740A (ja) | 2014-01-23 |
| JP2014501740A5 true JP2014501740A5 (cg-RX-API-DMAC7.html) | 2015-10-15 |
| JP5861194B2 JP5861194B2 (ja) | 2016-02-16 |
Family
ID=46312954
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013544980A Expired - Fee Related JP5861194B2 (ja) | 2010-12-23 | 2011-12-21 | 選択的グルコシダーゼインヒビターおよびその使用 |
| JP2015230912A Active JP6322177B2 (ja) | 2010-12-23 | 2015-11-26 | 選択的グルコシダーゼインヒビターおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015230912A Active JP6322177B2 (ja) | 2010-12-23 | 2015-11-26 | 選択的グルコシダーゼインヒビターおよびその使用 |
Country Status (26)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080287375A1 (en) * | 2005-03-01 | 2008-11-20 | Simon Fraser University | Selective Glycosidase Inhibitors, Methods of Making Inhibitors, and Uses Thereof |
| JP5380293B2 (ja) | 2006-08-31 | 2014-01-08 | サイモン・フレーザー・ユニバーシティ | 選択的グリコシダーゼ阻害剤およびその使用 |
| AU2009276223B2 (en) * | 2008-08-01 | 2015-04-02 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| EP2569291B1 (en) | 2010-05-11 | 2016-04-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| EP2638052B1 (en) * | 2010-11-08 | 2017-03-22 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| BR112013016179A2 (pt) * | 2010-12-23 | 2018-07-10 | Alectos Therapeutics Inc | inibidores seletivos da glicosidase e usos dos mesmos. |
| WO2012126091A1 (en) | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012129651A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013000084A1 (en) * | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013000086A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9199949B2 (en) | 2011-06-27 | 2015-12-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| CA2845149C (en) | 2011-08-25 | 2019-12-31 | Merck Patent Gmbh | Pyrano[3,2-d] [1,3]thiazole as glycosidase inhibitors |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| US9809537B2 (en) | 2012-08-31 | 2017-11-07 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| JP2015534991A (ja) * | 2012-10-31 | 2015-12-07 | アレクトス・セラピューティクス・インコーポレイテッド | グリコシダーゼ阻害剤およびその使用 |
| WO2014100934A1 (en) * | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| CA2958966C (en) | 2014-08-28 | 2020-01-14 | Asceneuron Sa | Substituted cyclic amines as glucosidase inhibitors |
| KR101777164B1 (ko) | 2015-07-20 | 2017-09-11 | 순천향대학교 산학협력단 | O-GlcNAc 트랜스퍼레즈 억제제용 UDP-GlcNAc의 C1-포스포네이트 유도체 |
| AR106977A1 (es) * | 2015-12-14 | 2018-03-07 | Amicus Therapeutics Inc | Compuestos para el tratamiento de la enfermedad de alzheimer y/o la angiopatía amiloide cerebral |
| WO2017144637A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Acid addition salts of piperazine derivatives |
| CA3012624A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| WO2017144633A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Glycosidase inhibitors |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| CN107814773B (zh) * | 2017-11-13 | 2020-05-22 | 西安交通大学 | 含有喹唑啉酮的二芳基脲类化合物及其制备方法和应用 |
| US20210115040A1 (en) * | 2018-06-20 | 2021-04-22 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| MX2021002111A (es) * | 2018-08-22 | 2021-07-16 | Asceneuron S A | Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa. |
| US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
| WO2020039027A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Pyrrolidine glycosidase inhibitors |
| CN114174263B (zh) * | 2019-05-10 | 2025-01-10 | 阿勒克图治疗公司 | 非溶酶体葡糖神经酰胺酶抑制剂及其用途 |
| CN111956656B (zh) * | 2020-08-28 | 2021-10-15 | 河北大学 | Oga抑制剂在制备抗肿瘤药物中的应用 |
| WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS423500Y1 (cg-RX-API-DMAC7.html) | 1964-02-29 | 1967-03-01 | ||
| DE2632243C3 (de) | 1976-07-17 | 1979-08-30 | Heidelberger Druckmaschinen Ag, 6900 Heidelberg | Auf variable Bogenlängen einstellbare Umführtrommel für Druckmaschinen |
| DE3620645A1 (de) | 1985-12-20 | 1987-07-02 | Bayer Ag | 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung |
| EP0243686B1 (en) | 1986-03-27 | 1992-07-15 | Sumitomo Pharmaceuticals Company, Limited | Beta-lactam compounds, and their production |
| SU1441749A1 (ru) * | 1987-03-16 | 1996-01-10 | Институт Тонкой Органической Химии Им.А.Л.Мнджояна | 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ |
| JPS6461459A (en) | 1987-08-28 | 1989-03-08 | Nippon Shinyaku Co Ltd | Moranoline derivative |
| JPH01180894A (ja) | 1988-01-07 | 1989-07-18 | Wako Pure Chem Ind Ltd | アミノ糖誘導体の新規な製造法 |
| GB8900719D0 (en) | 1989-01-13 | 1989-03-08 | Nycomed As | Compounds |
| US5079254A (en) | 1990-06-04 | 1992-01-07 | Merrell Dow Pharmaceuticals Inc. | Derivatives of 6-aminooctahydroindolizinetriol |
| WO1992003415A1 (en) | 1990-08-14 | 1992-03-05 | Nova Pharmaceutical Corporation | Protein kinase c modulators |
| US5276120A (en) | 1991-05-30 | 1994-01-04 | The Scripps Research Institute | Process for forming omega-deuxy-azasugars |
| US6291657B1 (en) | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
| US5451679A (en) | 1994-03-08 | 1995-09-19 | G. D. Searle & Co. | 2-chloro and 2-bromo derivatives of 1,5-iminosugars |
| JPH07316178A (ja) | 1994-05-25 | 1995-12-05 | Sankyo Co Ltd | 糖アミノオキサゾリン類 |
| CN1131672A (zh) | 1994-11-22 | 1996-09-25 | 生化学工业株式会社 | 氨基环戊烷衍生物 |
| CA2235415A1 (en) | 1995-09-08 | 1997-03-13 | Novo Nordisk A/S | 2-alkylpyrrolidines |
| CZ120398A3 (cs) | 1995-09-08 | 1998-12-16 | Novo Nordisk A/S | Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty |
| JPH09132585A (ja) | 1995-11-10 | 1997-05-20 | Shin Etsu Chem Co Ltd | 新規アミノ糖及びキトオリゴ糖又はその類似オリゴ糖の製造方法 |
| US6407103B2 (en) | 1998-04-21 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Indeno [1,2-c] pyrazol-4-ones and their uses |
| JPH11349541A (ja) | 1998-06-08 | 1999-12-21 | Sankyo Co Ltd | アロサミゾリン誘導体の新規な中間体 |
| GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| US6774140B1 (en) | 1999-05-11 | 2004-08-10 | The Scripps Research Institute | Iminocyclitol inhibitors of hexoaminidase and glycosidase |
| DE60045217D1 (de) | 1999-05-11 | 2010-12-23 | Scripps Research Inst | Iminocyclitol-inhibitoren von hexoaminidase und glycosidase |
| FR2817472B1 (fr) | 2000-12-06 | 2003-01-03 | Oreal | Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre |
| ATE509117T1 (de) | 2001-03-14 | 2011-05-15 | Denki Kagaku Kogyo Kk | Herstellungsverfahren für hyaluronsäure oder ihre derivate |
| JP4233262B2 (ja) | 2001-03-14 | 2009-03-04 | 生化学工業株式会社 | カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤 |
| WO2003008379A1 (en) | 2001-06-08 | 2003-01-30 | Mitsubishi Chemical Corporation | Azasugar compounds |
| JP4866515B2 (ja) | 2001-07-02 | 2012-02-01 | 生化学工業株式会社 | 糖オキサゾリン誘導体の製造方法 |
| WO2003009808A2 (en) | 2001-07-24 | 2003-02-06 | Yale University | Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
| CA2526173A1 (en) | 2003-05-22 | 2004-12-02 | The Hospital For Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| CN1548053A (zh) | 2003-05-23 | 2004-11-24 | 华晶基因技术有限公司 | 黄芩甙作为治疗焦虑症的药物的新用途 |
| WO2005026156A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005072268A2 (en) | 2004-01-20 | 2005-08-11 | Optimer Pharmaceuticals, Inc. | Treatment of degeneraative cartilage conditions in a mammal with glycosidase inhibitors |
| US20080166323A1 (en) | 2004-04-14 | 2008-07-10 | Uab Research Foundation | Activators of Hexosamine Biosynthesis as Inhibitors of Injury Induced by Ischemia or Hermorrhagic Shock |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| WO2006008194A1 (en) | 2004-07-23 | 2006-01-26 | Bayer Cropscience Sa | 3-pyridinylethylcarboxamide derivatives as fungicides |
| EP1789413A1 (en) | 2004-09-13 | 2007-05-30 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US7884115B2 (en) | 2004-09-28 | 2011-02-08 | Allergan, Inc. | Methods and compositions for the treatment of pain and other neurological conditions |
| US20080287375A1 (en) | 2005-03-01 | 2008-11-20 | Simon Fraser University | Selective Glycosidase Inhibitors, Methods of Making Inhibitors, and Uses Thereof |
| AT502145B1 (de) | 2005-03-24 | 2012-01-15 | Univ Graz Tech | Glycosidase-hemmendes iminoalditol |
| US7820699B2 (en) | 2005-04-27 | 2010-10-26 | Hoffmann-La Roche Inc. | Cyclic amines |
| US20070111981A1 (en) | 2005-10-26 | 2007-05-17 | Roth Gerald J | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds |
| WO2007067515A2 (en) | 2005-12-05 | 2007-06-14 | Academia Sinica | Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics |
| JP5380293B2 (ja) | 2006-08-31 | 2014-01-08 | サイモン・フレーザー・ユニバーシティ | 選択的グリコシダーゼ阻害剤およびその使用 |
| CN107253970A (zh) * | 2006-08-31 | 2017-10-17 | 西蒙·弗雷瑟大学 | 选择性糖苷酶抑制剂及其用途 |
| US8258307B2 (en) | 2006-11-07 | 2012-09-04 | University Of Tokyo | Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same |
| CA2732335A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| AU2009276223B2 (en) | 2008-08-01 | 2015-04-02 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US20110195929A1 (en) | 2008-08-05 | 2011-08-11 | Summit Corporation Plc | Compounds for the treatment of flaviviral infections |
| EP2323652A2 (en) | 2008-08-06 | 2011-05-25 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| AU2009299073B2 (en) | 2008-09-16 | 2015-04-02 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2010049678A2 (en) | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
| AT507745B1 (de) | 2008-12-16 | 2012-01-15 | Forschungsholding Tu Graz Gmbh | Fluorophile glykosidasehemmer |
| WO2011060397A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | Substituted amino heterocycles useful as hiv antagonists |
| EP2569291B1 (en) | 2010-05-11 | 2016-04-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| TW201249848A (en) | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| WO2012061971A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US8901087B2 (en) | 2010-11-08 | 2014-12-02 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| WO2012061972A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2638052B1 (en) | 2010-11-08 | 2017-03-22 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| BR112013016179A2 (pt) * | 2010-12-23 | 2018-07-10 | Alectos Therapeutics Inc | inibidores seletivos da glicosidase e usos dos mesmos. |
| GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
| JP6277121B2 (ja) | 2011-03-22 | 2018-02-07 | アドヴィナス・セラピューティックス・リミテッド | 置換された縮合三環式化合物、その組成物および医学的応用 |
| WO2012126091A1 (en) | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012129802A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof |
| WO2012129651A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9199949B2 (en) | 2011-06-27 | 2015-12-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013000086A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013000084A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2744338B1 (en) | 2011-08-18 | 2016-04-27 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| CA2845149C (en) | 2011-08-25 | 2019-12-31 | Merck Patent Gmbh | Pyrano[3,2-d] [1,3]thiazole as glycosidase inhibitors |
| EP2847199B1 (en) | 2012-05-08 | 2017-10-25 | Merck Sharp & Dohme Corp. | Permeable glycosidase inhibitors and uses thereof |
| US9809537B2 (en) | 2012-08-31 | 2017-11-07 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| US20150299122A1 (en) | 2012-08-31 | 2015-10-22 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| US9522883B2 (en) | 2012-08-31 | 2016-12-20 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| JP2015534991A (ja) | 2012-10-31 | 2015-12-07 | アレクトス・セラピューティクス・インコーポレイテッド | グリコシダーゼ阻害剤およびその使用 |
| WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
-
2011
- 2011-12-21 BR BR112013016179A patent/BR112013016179A2/pt not_active Application Discontinuation
- 2011-12-21 JP JP2013544980A patent/JP5861194B2/ja not_active Expired - Fee Related
- 2011-12-21 EP EP11850773.0A patent/EP2655388B1/en active Active
- 2011-12-21 NZ NZ612703A patent/NZ612703A/en not_active IP Right Cessation
- 2011-12-21 LT LTEP11850773.0T patent/LT2655388T/lt unknown
- 2011-12-21 CN CN201180066766.4A patent/CN103339138B/zh not_active Expired - Fee Related
- 2011-12-21 ES ES11850773.0T patent/ES2589164T3/es active Active
- 2011-12-21 CA CA2822493A patent/CA2822493C/en not_active Expired - Fee Related
- 2011-12-21 DK DK11850773.0T patent/DK2655388T3/en active
- 2011-12-21 HR HRP20161079TT patent/HRP20161079T1/hr unknown
- 2011-12-21 HU HUE11850773A patent/HUE030624T2/en unknown
- 2011-12-21 US US13/997,484 patent/US9243020B2/en not_active Expired - Fee Related
- 2011-12-21 MX MX2013007434A patent/MX343822B/es active IP Right Grant
- 2011-12-21 PT PT118507730T patent/PT2655388T/pt unknown
- 2011-12-21 TW TW100147743A patent/TWI572609B/zh not_active IP Right Cessation
- 2011-12-21 PL PL11850773.0T patent/PL2655388T3/pl unknown
- 2011-12-21 KR KR1020137019485A patent/KR101979036B1/ko not_active Expired - Fee Related
- 2011-12-21 RU RU2013134345A patent/RU2609210C2/ru not_active IP Right Cessation
- 2011-12-21 MY MYPI2013002307A patent/MY165728A/en unknown
- 2011-12-21 AU AU2011349021A patent/AU2011349021B2/en not_active Ceased
- 2011-12-21 WO PCT/CA2011/001397 patent/WO2012083435A1/en not_active Ceased
- 2011-12-22 AR ARP110104876 patent/AR085004A1/es active IP Right Grant
-
2013
- 2013-06-19 IL IL227055A patent/IL227055A/en active IP Right Grant
- 2013-07-22 CO CO13173187A patent/CO6821931A2/es active IP Right Grant
- 2013-07-22 ZA ZA2013/05531A patent/ZA201305531B/en unknown
-
2015
- 2015-11-26 JP JP2015230912A patent/JP6322177B2/ja active Active
- 2015-12-11 US US14/966,221 patent/US9815861B2/en not_active Expired - Fee Related
-
2016
- 2016-09-07 CY CY20161100886T patent/CY1118157T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501740A5 (cg-RX-API-DMAC7.html) | ||
| JP2014524911A5 (cg-RX-API-DMAC7.html) | ||
| JP2015534991A5 (cg-RX-API-DMAC7.html) | ||
| RU2013134345A (ru) | Селективные ингибиторы гликозидазы и их применение | |
| JP2010501598A5 (cg-RX-API-DMAC7.html) | ||
| RU2014102232A (ru) | Селективные ингибиторы гликозидазы и их применение | |
| JP2012502884A5 (cg-RX-API-DMAC7.html) | ||
| JP2013541596A5 (cg-RX-API-DMAC7.html) | ||
| RU2015120556A (ru) | Ингибиторы гликозидаз и их применения | |
| JP6218260B2 (ja) | Ｊａｋ阻害剤としてのアミノピリミジニル化合物 | |
| JP2011529858A5 (cg-RX-API-DMAC7.html) | ||
| JP2011529857A5 (cg-RX-API-DMAC7.html) | ||
| WO2008025170B1 (en) | Selective glycosidase inhibitors and uses thereof | |
| JP6740354B2 (ja) | オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 | |
| SI2956452T1 (en) | Heterocyclic amides as kinase inhibitors | |
| TW200911254A (en) | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842 | |
| CN100475813C (zh) | 4-氧代-1-(3-取代苯基)-1,4-二氢-1,8-萘啶-3-甲酰胺磷酸二酯酶-4抑制剂 | |
| JP2004505973A (ja) | ブラジキニンアンタゴニストとしての１，４−ジヒドロピリジン類 | |
| KR102602998B1 (ko) | 억제제 및 이의 사용 | |
| US10835624B2 (en) | Compounds for imaging Tau protein aggregates | |
| JP2017538753A5 (cg-RX-API-DMAC7.html) | ||
| US9464103B2 (en) | Spirocyclic sulfones as gamma secretase inhibitors | |
| JPWO2021262484A5 (cg-RX-API-DMAC7.html) | ||
| JP2018515536A (ja) | カゼインキナーゼ１δ阻害剤 | |
| CA2601458A1 (en) | Benzimidazolone derivatives as cb2 receptor ligands |